Understanding Minimal Residual Disease Using Genetically Modified Blood Cancer Models
Minimal residual disease (MRD) refers to the small population of cancer cells that survive initial therapy and may cause relapse. Detecting and understanding MRD is critical for improving long-term outcomes in blood cancers.
Genetically modified blood cancer models expressing fluorescent or luminescent reporter genes allow researchers to sensitively track residual tumor cells in vivo and in vitro. These models enable real-time monitoring of tumor burden following treatment, providing insights into MRD dynamics.
By applying advanced imaging and flow cytometry techniques, investigators can characterize MRD cells’ phenotypes, resistance mechanisms, and interactions with the microenvironment. This understanding helps identify therapeutic vulnerabilities and develop treatments aimed at eradicating MRD.
Preclinical models mimicking MRD conditions facilitate testing of novel drugs or combination regimens designed to prevent relapse, a major challenge in leukemia and lymphoma management.
Harnessing genetic modification and sensitive detection methods strengthens MRD research, ultimately guiding personalized treatment strategies.
References: Altogen.com Altogenlabs.com